Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Group 1 - Cocrystal Pharma, Inc. closed a registered direct offering, raising approximately $4.7 million from the sale of 2,764,710 shares at a price of $1.70 per share [1][3] - The company also issued unregistered warrants for the purchase of up to 5,529,420 shares at an exercise price of $1.50 per share, potentially adding approximately $8.3 million in gross proceeds if fully exercised [1][3] - The net proceeds from the offering will be used for working capital and general corporate purposes [3] Group 2 - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2] - The common stock was offered under a "shelf" registration statement effective since May 26, 2023, with a final prospectus supplement filed with the SEC [4] - The unregistered warrants were offered in a private placement and have not been registered under the Securities Act [5] Group 3 - Cocrystal Pharma is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [7]